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Introduction 
 
In the primary health care setting, quite a substantial amount of information on patients is already 
available within various health-related computer systems [1]. This sort of data is the basic ingredient of 
so-called electronic health care records (EHRs). It provides a first step to digitised personal healthcare, 
in so far as the GPs are able to monitor routine aspects of the treatment and health records of their 
patients. Today, quite a few reasonably sophisticated data acquisition methods are available in the 
average GP’s surgery. Patients are already using simple devices to monitor their conditions and, to some 
extent, take control of the management of their own diseases. What is lacking is the ability of 
consultants, clinicians, nurses and doctors to be linked together to the wider healthcare system 
comprising both primary and secondary (hospital) environments, where the most challenging medical 
activities and procedures are implemented, often involving life or death decisions.  
Insofar as patient empowerment must be at the centre of the dawning revolution, the current situation in 
primary healthcare is still far from adequate. Patients in general are still unable to access their own data, 
still less to interact with it and to form social networks with fellow sufferers. Internet-based IT is set to 
change this; in future, patient groups will be increasingly self-educating and will need to rely less on 
direct interactions with the hospital. At the same time, doctors are increasingly having to deal with 
‘internet-savvy’ patients who today are able to find out more about their own condition than the GP 
administering to them. Ultimately, there is the wider issue of citizen empowerment, and the 
opportunities for commercial growth derived therefrom, reaching out through the Internet and high 
street pharmacists. The future citizen is likely to be able to marshal his or her own data and use it to make 
informed decisions to enhance their lifestyle, longevity, inter alia. 
e-Medicine for a Digital Me: Key to implementation 
 
E-medicine is set to facilitate all of this. To tackle health and well being on a personalised basis, we 
need to bring together and manage large-scale, heterogeneous, distributed, patient and citizen data to 
make a virtual human, just as Google maps draws on multi-resolution imagery to provide a detailed 
account of the Earth's geography. Building on the wealth of personalised data, medical science is now 
constructing reliable, integrated, computer models at all levels from the molecular to the entire human 
and even population levels – this is what is referred to today by the Virtual Physiological Human, and 
eventually, perhaps, a Digital Me (Fig. 1). Through new agreements in terms of patient consent, much 
patient data are likely to become research data in the near future. Levels of security and privacy afforded 
by internet banking will be implemented to allow patients to manage their own data and store it “in the 
cloud”. That data can then be pulled down for all manner of health related purposes, from emergency 
healthcare decision making to lifestyle choices for the apparently healthy. The data itself will 
accumulate from a number of acquisition routes, ranging from the GP’s surgery through to increasing 
levels of sophistication in the hospital context [2, 3].  
Gene sequencing and the associated omics capabilities are now at a stage where individuals can expect 
to acquire their entire genome within a matter of minutes. Information derived from the genome can be 
used to build personalised molecular models of proteins interacting with other proteins, DNA, RNA 
and, of course, drugs [4,5,6,7,8,9]. Imaging data, which provide a highly non-invasive route to exquisite 
three-dimensional representations of human organs and other structures, can also be used as the starting 
point for higher level – typically physiological – models of human pathology. And eventually, the two 
levels might be related via so-called genotype-phenotype mappings.  
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Drug design cannot continue to be done simply on the basis of attempting to design a single compound 
which targets one receptor or enzyme while ignoring the network of interactions of that protein with 
other biomolecules (including for example other proteins and nucleic acids such as DNA and RNA) 
with which it enjoys extensive interactions. Systems biology is the discipline which is concerned with 
teasing out the precise details of these often very extensive and complex interaction networks [10]. 
Ultimately, drug design must pay careful attention not only to very specific molecular interactions with 
one protein target, but also the way in which that interaction may impact, and be affected by, other 
interactions inside the network which are themselves altered not only by the presence of the drug but 
also by the consequence of the same or different genetic mutations. 
 
Figure 1. A ‘Digital Me’: from health to pathology [Courtesy of IT Future of Medicine Consortium] 
E-infrastructure 
Information technology is revolutionising medicine. We rely on advanced ICT infrastructures, not only 
to ease the administration of the day-to-day activities of the hospital, but also to aid the actual treatment 
of patients, through personalised, predictive simulation. The data contained in previously paper-based 
records can be integrated with data already in a digital form (such as imaging data) as well as the 
patient’s genetic profile, which is increasingly being generated as a matter of routine in the treatment of 
a number of conditions. This abundance of digital data also allows data mining and modelling 
techniques to be applied to data that would otherwise have lain dormant in filing cabinets. Such 
techniques can be used to spot correlations between cohorts of patients that would otherwise have gone 
unnoticed, and build patient specific models which assist the clinician in the better targeting of 
treatments to an individual. Models built from patient-derived data allow a clinician to assess the likely 
efficacy of a treatment on that patient before it is administered, potentially avoiding adverse outcomes 
and ineffective treatment regimes. Such model-based simulation techniques are now emerging from 
university research labs, and translation of such techniques from lab to routine is critical.   
The implementation of such IT infrastructure, to handle the ‘data deluge’, is hampered by legitimate 
concerns over patient data security and confidentiality. The need to move data outside of a clinical 
domain means that data either need to be anonymised, so that it cannot be used to identify a patient, 
and/or data protection agreements need to be in place between the institutions accessing the data. 
However, the benefits of overcoming these hurdles are clear in terms of more effective treatments and 
fostering interdisciplinary research collaborations; thus many efforts are underway to do so. An 
international effort of relevance is the NIH-funded Informatics for integrating Biology and the Bedside 
(i2b2) project, which aims to build an informatics infrastructure to support research by storing and 
integrating data from clinical practice, and making it available in anonymised form to researchers [11].  
A new breed of clinicians 
According to a new book ‘The Creative Destruction of Medicine’, 90% in large surveys of tens of thousands 
of doctors have said they are not comfortable or familiar with the use of genomic data in managing their 
patients. Many doctors are unwilling or reluctant to change the way they practice medicine. For 
example, although it might be more useful for sequencing and genomic research to freeze tumour 
samples, surgeons and pathologists most often store tissue in formalin, which tends to make meaningful 
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sequencing more difficult. None of this ought to be surprising, as the knowledge and training available 
today for the medical and clinical communities do not match the changing landscape of medical practice 
and personalised medicine to which we are now firmly headed. Still, patients trust their doctors the most 
with their data. So unless a new breed of physicians and clinicians is established, who are firmly 
grounded in the principles of biomedical modelling and its role in clinical decision-making, increasingly 
available patient information and medical/clinical data will simply gather dust. However, it is inevitable 
that, given a little time, clinical modellers will emerge to lead the revolution we are describing here. It is 
essential that such clinically trained people be in the vanguard of these new approaches or they will not 
succeed.  
 
Ethical, legal and privacy perspectives 
Armed with a wealth of information available at one's own fingertips through the click of a mouse 
button, global citizenry will be empowered as never before to address its own predicament – and to 
confront the unprecedented ethical problems that such vast amounts of information will inevitably also 
bring. Ethical, legal, and privacy implications of having one's data used for research will continue to be 
debated, until some regulatory body takes action or legal precedents are reached. It is important to 
remember it is still early days, and much of the regulatory procedure will become clear to the public, 
healthcare and IT providers as the technologies around personal genomics and clinical decision support 
are further explored. Still, one successful example is by Morris and co-workers who have shown that 
when patients are fully involved in a study and are aware of its value, they readily give consent for their 
data to be used [12]. The Scottish Health Informatics Platform defines the approach they adopt to data 
management as “proportionate governance”. Their approach is already being rolled out in Scotland and 
within some international health projects too. 
Conclusion 
It is manifest that medical science and its clinical applications can only be enhanced by the widespread 
but judicious use of information technology. This is already creating new domains requiring new forms 
of expertise – e-medicine and e-health. They are based on an ability to acquire and manage confidential 
personal data seamlessly across and throughout the healthcare system, and to use it in order to better 
treat individual patients. The data must be turned into useful information, often by combining it with a 
model and/or simulation, which helps the clinician to make decisions on treatment of the individual in 
front of him or her. Beyond these already compelling prospects for curing sick people, there is great 
potential for using computer-based tools to support clinical decision-making in the community at large, 
which will allow already knowledgeable patients to play a greater part in designing their own healthcare 
and lifestyles. Without a shadow of a doubt, medicine is transforming beyond recognition, and is set to 
become increasingly home-based.  
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